Empowering Pharmacists: South African Court Ruling Greenlights Pharmacist-Prescribed ARVs

By Staff Writer

August 16, 2023

In a landmark decision, the Pretoria High Court has given the South African Pharmacy Council (SAPC) the judicial green light to implement its Pharmacy-Initiated Management of Antiretroviral Treatment (PIMART) initiative. This allows specially trained pharmacists to manage and prescribe medicine to patients with HIV and tuberculosis.

Judge Elmarie van der Schyff dismissed an application by a doctors’ organisation, the IPA Foundation, to set aside the programme, stating the need for wider access to first-line ART and TPT therapy on a community level is a “dire need”.

The PIMART training course was created to qualify pharmacists in safely and effectively assisting in providing ART, upon successful completion.

This ruling is in line with the World Health Organization’s vision to promote widely accessible primary health care and recognizes the critical role pharmacies play in meeting healthcare needs, especially during pandemics like COVID-19.

Professor Francois Venter, former President of the Southern African HIV Clinicians Society and current Director of Ezintsha, an HIV research organisation, has emphasized the crucial role of pharmacies and pharmacists in expanding HIV services worldwide.

Let’s celebrate this win.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.